在癌中准HIF2驱动的缓解症
Muhannad Abu-Remaileh1,2, Laura A Stransky1, Nikita Bhalerao3
1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Nature medicine
|November 29, 2025
概括
清细胞细胞癌 (ccRCC) 通过HIF2驱动的PTHLH引起高热血和缓解症. 在癌患者中,HIF2抑制剂有效治疗这些副瘤综合征.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 癌,特别是清细胞细胞癌 (ccRCC),通常伴有诸如高血症和缓冲症之类的副瘤综合征.
- 在ccRCC中驱动这些综合征的分子机制尚未完全阐明.
- 失去pVHL瘤抑制蛋白和随后的HIF2上调是ccRCC发病过程中的关键事件.
研究的目的:
- 调查HIF2在CCRCC中介导瘤综合征中的作用.
- 为了确定HIF2的下游点,涉及高血症和缓冲症.
- 评估HIF2抑制剂在治疗这些综合征方面的治疗潜力.
主要方法:
- 在ccRCC中分析PTHLH作为直接的HIF2转录标.
- 临床前的正管瘤模型,以评估PTHLH在诱导缓解症和高血症中的必要性和充分性.
- 在ccRCC患者中对HIF2抑制剂 (belzutifan,NKT2152) 的临床评估.
主要成果:
- 在ccRCC中,PTHLH被确定为直接的HIF2转录标.
- 在临床前模型中,增加PTHLH表达被发现是诱导高血症和缓冲症的必要和充分因素.
- 在ccRCC患者中,HIF2抑制剂迅速改善了高血症和缓解症,而不管瘤缩小.
结论:
- HIF2驱动的PTHLH表达是ccRCC中高血症和缓解症的关键机制.
- HIF2抑制剂显示出对这些神经瘤综合征的治疗疗效.
- 需要进一步的临床研究来探索HIF2抑制剂用于治疗脏细胞癌症中与癌症相关的缓解症.
更多相关视频
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
11.8K
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
14.1K
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:53Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K